한글목차

항체 탐색 시장 규모는 제약 및 생명공학 분야를 재편하고 있는 기술 혁신과 기술 진보에 힘입어 크게 성장하고 있습니다. 업계는 파지 디스플레이 및 하이브리도마 기술과 같은 첨단 기술을 활용하여 표적화되고 효과적인 치료 솔루션을 제공하는 것을 목표로 하고 있습니다. 이러한 개발은 암, 자가면역질환, 감염성 질환과 같은 복잡한 질병에 대처하기 위해 필수적입니다.

세계 항체 탐색 시장은 꾸준히 성장하여 2025년에는 88억 8,800만 달러, 2032년에는 158억 2,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 8.60%의 CAGR을 기록할 것으로 예상됩니다. 이 시장의 확대는 고도로 특이적이고 효과적인 치료 중재를 제공함으로써 치료 방식에 혁명을 가져오는 인공지능의 중요한 역할을 뒷받침합니다. 인공지능과 맞춤형 의료의 발전은 이 시장의 혁신과 수익 창출 가능성을 더욱 높여주고 있습니다.

차세대 시퀀싱 및 고급 스크리닝 방법과 같은 고처리량 기술의 통합으로 항체 탐색이 가속화되고 있습니다. 이러한 기술 혁신은 효율성을 높이고 잠재적인 치료용 항체를 신속하게 식별할 수 있도록 돕습니다. 맞춤형 치료의 확산으로 항체 기반 맞춤형 치료에 대한 요구가 증가하고 있습니다. 이러한 추세는 개별 환자 프로필과 표적 질환 경로에 초점을 맞춘 정밀의료로의 전환과 일치합니다. 암, 자가면역질환 및 기타 만성질환의 발병률 증가는 혁신적인 치료 솔루션에 대한 수요를 강조하며 항체 탐색 부문을 의료 발전의 최전선에 위치시키고 있습니다.

세계의 항체 탐색 시장에 대해 조사했으며, 시장 개요와 함께 방법별, 항체 종류별, 최종 용도별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등의 정보를 전해드립니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나·러시아 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 항체 탐색 시장 전망, 2019-2032년

• 세계의 항체 탐색 시장 전망, 방법별, 금액(10억 달러), 2019-2032년
• 세계의 항체 탐색 시장 전망, 항체 유형별, 금액(10억 달러), 2019-2032년
• 세계의 항체 탐색 시장 전망, 최종 용도별, 금액(10억 달러), 2019-2032년
• 세계의 항체 탐색 시장 전망, 지역별, 금액(10억 달러), 2019-2032년

제4장 북미의 항체 탐색 시장 전망, 2019-2032년

제5장 유럽의 항체 탐색 시장 전망, 2019-2032년

제6장 아시아태평양의 항체 탐색 시장 전망, 2019-2032년

제7장 라틴아메리카의 항체 탐색 시장 전망, 2019-2032년

제8장 중동 및 아프리카의 항체 탐색 시장 전망, 2019-2032년

제9장 경쟁 구도

• 방법별 vs항체 유형별 히트맵
• 기업 시장 점유율 분석, 2025년
• 경쟁 대시보드
• 기업 개요
  • Alcami Corporation, Inc.
  • BASF SE
  • Bioduro-Sundia
  • Bruker
  • Cambrex Corporation
  • Croda International Plc
  • Aragen Life Sciences Pvt. Ltd
  • Eurofins DiscoverX Corporation
  • NanoCellect Biomedical
  • Sartorius AG

제10장 부록

영문목차

The Antibody Discovery Market is set to achieve significant growth, driven by innovations and technological advancements that are reshaping the pharmaceutical and biotechnology sectors. By leveraging cutting-edge techniques such as phage display and hybridoma technology, the industry aims to deliver targeted and effective therapeutic solutions. These developments are critical for addressing complex diseases such as cancer, autoimmune disorders, and infectious diseases.

Market Insights

The global Antibody Discovery Market is projected to grow steadily, achieving a valuation of $8.88 billion by 2025 and $15.82 billion by 2032, with a CAGR of 8.60% during the forecast period. The market's expansion underscores its vital role in revolutionizing treatment modalities by providing highly specific and effective therapeutic interventions. Advances in artificial intelligence and personalized medicine further fuel the market's potential for innovation and revenue generation.

Key Market Drivers

• 1. Advancements in Biotechnology: The integration of high-throughput technologies, such as next-generation sequencing and advanced screening methods, is expediting antibody discovery. These innovations enhance efficiency, enabling faster identification of potential therapeutic antibodies.
• 2. Rising Demand for Personalized Medicine: Tailored therapies are gaining traction, driving the need for customized antibody-based treatments. This trend aligns with the shift toward precision medicine, focusing on individual patient profiles and targeted disease pathways.
• 3. Increased Prevalence of Chronic Diseases: The growing burden of cancer, autoimmune disorders, and other chronic illnesses emphasizes the demand for innovative therapeutic solutions, positioning the antibody discovery sector at the forefront of medical advancements.

Business Opportunities

• 1. Innovative Collaboration Models: Strategic partnerships with academic institutions, biotechnology firms, and contract research organizations present lucrative opportunities. These collaborations enable resource-sharing and expedite the discovery and development of novel therapeutic antibodies.
• 2. Integration of Artificial Intelligence: Leveraging AI algorithms enhances antibody design, screening, and optimization processes, accelerating the identification of high-affinity and highly specific antibodies. This technological integration offers a competitive edge to market players.
• 3. Emerging Markets in South Asia & Pacific: Countries in this region, including India, China, and Australia, are investing heavily in biomedical research. Collaborative initiatives between academic institutions and pharmaceutical companies amplify the region's potential as a hub for antibody discovery.

Regional Analysis

• Europe: The region is emerging as a dominant force in the market, driven by a robust research infrastructure and a proactive regulatory environment. Europe's streamlined approval processes and focus on innovation foster market growth and attract significant investments.
• North America: As a global leader in biotechnology and pharmaceutical research, North America's advanced infrastructure and strong funding ecosystem position it as a key contributor to market expansion.
• South Asia & Pacific: This region is witnessing the fastest growth, fueled by increased research initiatives and collaborations aimed at addressing complex diseases. The region's commitment to advancing life sciences strengthens its role in the global market.

Market Challenges

• 1. Regulatory Stringency: Stringent regulatory frameworks governing the development and approval of antibody-based therapeutics can slow market progression. Companies must ensure compliance to gain market dominance.
• 2. Technological Complexity: The integration of diverse platforms and techniques, such as phage display and hybridoma, requires substantial expertise and investment. Addressing these challenges is essential for streamlined operations.

Recent Developments

• 1. Strategic Collaborations: Regeneron Pharmaceuticals, Inc., and Intellia Therapeutics, Inc., expanded their research collaboration in 2023 to develop in vivo CRISPR-based gene-editing therapies targeting neurological and muscular diseases.
• 2. Strengthening R&D: In September 2022, Abzena announced strategic initiatives to enhance its research capabilities in Cambridge, reinforcing its position in biologics and antibody drug conjugates.

Key Players

Prominent organizations driving innovation in the Antibody Discovery Market include:

• Alcami Corporation, Inc.
• BASF SE
• Bioduro-Sundia
• Bruker
• Cambrex Corporation
• Croda International Plc
• Aragen Life Sciences Pvt. Ltd
• Eurofins DiscoverX Corporation
• NanoCellect Biomedical
• Sartorius AG

Market Segmentation

1. By Method:

Phage Display Hybridoma Others

2. By Antibody Type:

Humanized Antibody Human Antibody Chimeric Antibody Murine Antibody

3. By End-Use:

Pharmaceutical and Biotechnology Industry Research Laboratory Academic Laboratory

4. By Region:

North America Europe East Asia South Asia & Oceania Latin America Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Antibody Discovery Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2025
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Antibody Discovery Market Outlook, 2019 - 2032

• 3.1. Global Antibody Discovery Market Outlook, by Method, Value (US$ Bn), 2019 - 2032
  • 3.1.1. Key Highlights
    • 3.1.1.1. Phage Display
    • 3.1.1.2. Hybridoma
    • 3.1.1.3. Others
• 3.2. Global Antibody Discovery Market Outlook, by Antibody Type, Value (US$ Bn), 2019 - 2032
  • 3.2.1. Key Highlights
    • 3.2.1.1. Humanized Antibody
    • 3.2.1.2. Human Antibody
    • 3.2.1.3. Chimeric Antibody
    • 3.2.1.4. Murine Antibody
• 3.3. Global Antibody Discovery Market Outlook, by End-use, Value (US$ Bn), 2019 - 2032
  • 3.3.1. Key Highlights
    • 3.3.1.1. Pharmaceutical and Biotechnology industry
    • 3.3.1.2. Research laboratory
    • 3.3.1.3. Academic laboratory
• 3.4. Global Antibody Discovery Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
  • 3.4.1. Key Highlights
    • 3.4.1.1. North America
    • 3.4.1.2. Europe
    • 3.4.1.3. Asia Pacific
    • 3.4.1.4. Latin America
    • 3.4.1.5. Middle East & Africa

4. North America Antibody Discovery Market Outlook, 2019 - 2032

• 4.1. North America Antibody Discovery Market Outlook, by Method, Value (US$ Bn), 2019 - 2032
  • 4.1.1. Key Highlights
    • 4.1.1.1. Phage Display
    • 4.1.1.2. Hybridoma
    • 4.1.1.3. Others
• 4.2. North America Antibody Discovery Market Outlook, by Antibody Type, Value (US$ Bn), 2019 - 2032
  • 4.2.1. Key Highlights
    • 4.2.1.1. Humanized Antibody
    • 4.2.1.2. Human Antibody
    • 4.2.1.3. Chimeric Antibody
    • 4.2.1.4. Murine Antibody
• 4.3. North America Antibody Discovery Market Outlook, by End-use, Value (US$ Bn), 2019 - 2032
  • 4.3.1. Key Highlights
    • 4.3.1.1. Pharmaceutical and Biotechnology industry
    • 4.3.1.2. Research laboratory
    • 4.3.1.3. Academic laboratory
  • 4.3.2. BPS Analysis/Market Attractiveness Analysis
• 4.4. North America Antibody Discovery Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 4.4.1. Key Highlights
    • 4.4.1.1. Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 4.4.1.2. Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 4.4.1.3. Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 4.4.1.4. Canada Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 4.4.1.5. Canada Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 4.4.1.6. Canada Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
  • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Antibody Discovery Market Outlook, 2019 - 2032

• 5.1. Europe Antibody Discovery Market Outlook, by Method, Value (US$ Bn), 2019 - 2032
  • 5.1.1. Key Highlights
    • 5.1.1.1. Phage Display
    • 5.1.1.2. Hybridoma
    • 5.1.1.3. Others
• 5.2. Europe Antibody Discovery Market Outlook, by Antibody Type, Value (US$ Bn), 2019 - 2032
  • 5.2.1. Key Highlights
    • 5.2.1.1. Humanized Antibody
    • 5.2.1.2. Human Antibody
    • 5.2.1.3. Chimeric Antibody
    • 5.2.1.4. Murine Antibody
• 5.3. Europe Antibody Discovery Market Outlook, by End-use, Value (US$ Bn), 2019 - 2032
  • 5.3.1. Key Highlights
    • 5.3.1.1. Pharmaceutical and Biotechnology industry
    • 5.3.1.2. Research laboratory
    • 5.3.1.3. Academic laboratory
  • 5.3.2. BPS Analysis/Market Attractiveness Analysis
• 5.4. Europe Antibody Discovery Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 5.4.1. Key Highlights
    • 5.4.1.1. Germany Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 5.4.1.2. Germany Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.3. Germany Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 5.4.1.4. U.K. Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 5.4.1.5. U.K. Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.6. U.K. Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 5.4.1.7. France Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 5.4.1.8. France Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.9. France Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 5.4.1.10. Italy Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 5.4.1.11. Italy Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.12. Italy Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 5.4.1.13. Turkey Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 5.4.1.14. Turkey Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.15. Turkey Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 5.4.1.16. Russia Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 5.4.1.17. Russia Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.18. Russia Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 5.4.1.19. Rest of Europe Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 5.4.1.20. Rest of Europe Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 5.4.1.21. Rest of Europe Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
  • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Antibody Discovery Market Outlook, 2019 - 2032

• 6.1. Asia Pacific Antibody Discovery Market Outlook, by Method, Value (US$ Bn), 2019 - 2032
  • 6.1.1. Key Highlights
    • 6.1.1.1. Phage Display
    • 6.1.1.2. Hybridoma
    • 6.1.1.3. Others
• 6.2. Asia Pacific Antibody Discovery Market Outlook, by Antibody Type, Value (US$ Bn), 2019 - 2032
  • 6.2.1. Key Highlights
    • 6.2.1.1. Humanized Antibody
    • 6.2.1.2. Human Antibody
    • 6.2.1.3. Chimeric Antibody
    • 6.2.1.4. Murine Antibody
• 6.3. Asia Pacific Antibody Discovery Market Outlook, by End-use, Value (US$ Bn), 2019 - 2032
  • 6.3.1. Key Highlights
    • 6.3.1.1. Pharmaceutical and Biotechnology industry
    • 6.3.1.2. Research laboratory
    • 6.3.1.3. Academic laboratory
  • 6.3.2. BPS Analysis/Market Attractiveness Analysis
• 6.4. Asia Pacific Antibody Discovery Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 6.4.1. Key Highlights
    • 6.4.1.1. China Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 6.4.1.2. China Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.3. China Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 6.4.1.4. Japan Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 6.4.1.5. Japan Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.6. Japan Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 6.4.1.7. South Korea Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 6.4.1.8. South Korea Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.9. South Korea Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 6.4.1.10. India Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 6.4.1.11. India Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.12. India Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 6.4.1.13. Southeast Asia Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 6.4.1.14. Southeast Asia Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.15. Southeast Asia Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 6.4.1.16. Rest of Asia Pacific Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 6.4.1.17. Rest of Asia Pacific Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 6.4.1.18. Rest of Asia Pacific Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
  • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Antibody Discovery Market Outlook, 2019 - 2032

• 7.1. Latin America Antibody Discovery Market Outlook, by Method, Value (US$ Bn), 2019 - 2032
  • 7.1.1. Key Highlights
    • 7.1.1.1. Phage Display
    • 7.1.1.2. Hybridoma
    • 7.1.1.3. Others
• 7.2. Latin America Antibody Discovery Market Outlook, by Antibody Type, Value (US$ Bn), 2019 - 2032
  • 7.2.1. Key Highlights
    • 7.2.1.1. Humanized Antibody
    • 7.2.1.2. Human Antibody
    • 7.2.1.3. Chimeric Antibody
    • 7.2.1.4. Murine Antibody
• 7.3. Latin America Antibody Discovery Market Outlook, by End-use, Value (US$ Bn), 2019 - 2032
  • 7.3.1. Key Highlights
    • 7.3.1.1. Pharmaceutical and Biotechnology industry
    • 7.3.1.2. Research laboratory
    • 7.3.1.3. Academic laboratory
  • 7.3.2. BPS Analysis/Market Attractiveness Analysis
• 7.4. Latin America Antibody Discovery Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 7.4.1. Key Highlights
    • 7.4.1.1. Brazil Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 7.4.1.2. Brazil Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.3. Brazil Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 7.4.1.4. Mexico Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 7.4.1.5. Mexico Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.6. Mexico Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 7.4.1.7. Argentina Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 7.4.1.8. Argentina Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.9. Argentina Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 7.4.1.10. Rest of Latin America Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 7.4.1.11. Rest of Latin America Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 7.4.1.12. Rest of Latin America Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
  • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Antibody Discovery Market Outlook, 2019 - 2032

• 8.1. Middle East & Africa Antibody Discovery Market Outlook, by Method, Value (US$ Bn), 2019 - 2032
  • 8.1.1. Key Highlights
    • 8.1.1.1. Phage Display
    • 8.1.1.2. Hybridoma
    • 8.1.1.3. Others
• 8.2. Middle East & Africa Antibody Discovery Market Outlook, by Antibody Type, Value (US$ Bn), 2019 - 2032
  • 8.2.1. Key Highlights
    • 8.2.1.1. Humanized Antibody
    • 8.2.1.2. Human Antibody
    • 8.2.1.3. Chimeric Antibody
    • 8.2.1.4. Murine Antibody
• 8.3. Middle East & Africa Antibody Discovery Market Outlook, by End-use, Value (US$ Bn), 2019 - 2032
  • 8.3.1. Key Highlights
    • 8.3.1.1. Pharmaceutical and Biotechnology industry
    • 8.3.1.2. Research laboratory
    • 8.3.1.3. Academic laboratory
  • 8.3.2. BPS Analysis/Market Attractiveness Analysis
• 8.4. Middle East & Africa Antibody Discovery Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
  • 8.4.1. Key Highlights
    • 8.4.1.1. GCC Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 8.4.1.2. GCC Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.3. GCC Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 8.4.1.4. South Africa Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 8.4.1.5. South Africa Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.6. South Africa Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 8.4.1.7. Egypt Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 8.4.1.8. Egypt Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.9. Egypt Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 8.4.1.10. Nigeria Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 8.4.1.11. Nigeria Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.12. Nigeria Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
    • 8.4.1.13. Rest of Middle East & Africa Antibody Discovery Market by Method, Value (US$ Bn), 2019 - 2032
    • 8.4.1.14. Rest of Middle East & Africa Antibody Discovery Market by Antibody Type, Value (US$ Bn), 2019 - 2032
    • 8.4.1.15. Rest of Middle East & Africa Antibody Discovery Market by End-use, Value (US$ Bn), 2019 - 2032
  • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. By Method vs by Antibody Type Heat map
• 9.2. Company Market Share Analysis, 2025
• 9.3. Competitive Dashboard
• 9.4. Company Profiles
  • 9.4.1. Alcami Corporation, Inc.
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Product Portfolio
    • 9.4.1.3. Financial Overview
    • 9.4.1.4. Business Strategies and Development
  • 9.4.2. BASF SE
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Product Portfolio
    • 9.4.2.3. Financial Overview
    • 9.4.2.4. Business Strategies and Development
  • 9.4.3. Bioduro-Sundia
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Product Portfolio
    • 9.4.3.3. Financial Overview
    • 9.4.3.4. Business Strategies and Development
  • 9.4.4. Bruker
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Product Portfolio
    • 9.4.4.3. Financial Overview
    • 9.4.4.4. Business Strategies and Development
  • 9.4.5. Cambrex Corporation
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Product Portfolio
    • 9.4.5.3. Financial Overview
    • 9.4.5.4. Business Strategies and Development
  • 9.4.6. Croda International Plc
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Product Portfolio
    • 9.4.6.3. Financial Overview
    • 9.4.6.4. Business Strategies and Development
  • 9.4.7. Aragen Life Sciences Pvt. Ltd
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Product Portfolio
    • 9.4.7.3. Financial Overview
    • 9.4.7.4. Business Strategies and Development
  • 9.4.8. Eurofins DiscoverX Corporation
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Product Portfolio
    • 9.4.8.3. Financial Overview
    • 9.4.8.4. Business Strategies and Development
  • 9.4.9. NanoCellect Biomedical
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Product Portfolio
    • 9.4.9.3. Financial Overview
    • 9.4.9.4. Business Strategies and Development
  • 9.4.10. Sartorius AG
    • 9.4.10.1. Company Overview
    • 9.4.10.2. Product Portfolio
    • 9.4.10.3. Financial Overview
    • 9.4.10.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations